Lenvatinib mesylate is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Henan Cancer Hospital (1). The most-studied condition is Effectiveness.
Of the three regulators tracked here, the first to approve Lenvatinib mesylate was the US, on 13 Feb 2015. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Protections still running for marketed products containing Lenvatinib mesylate, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
Reproduced from the FDA Orange Book and Purple Book (checked 28 Sep 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
NCT05342194 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma
|
Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd | China |
|
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
NCT05617859 · ClinicalTrials.gov ↗ · Effectiveness, Sexuality
|
Phase 2 | Recruiting | Henan Cancer Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Henan Cancer Hospital | 1 |
| Shanghai Junshi Bioscience Co., Ltd | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Lenvatinib mesylate as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Henan Cancer Hospital (1) and Shanghai Junshi Bioscience Co., Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Lenvatinib mesylate works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lenvatinib mesylate works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lenvatinib mesylate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.